Literature DB >> 29771043

[The effect of tanshinone ⅡA potentiates the effects of Cisplatin in Fadu cells in vitro through downregulation of survivin].

Y X Zhao1, D Luo1, Y H Zhang1, B Shen1, B X Wang1, Z F Sun1.   

Abstract

Objective:The aim of this study is to investigate the inhibitory effect and mechanism of tanshinone ⅡA combined with cisplatin on tumor Fadu cells in pharyngeal squamous cell carcinoma. Method:Cytotoxicity was determined by CCK8 assay. Flow cytometry was used to detect apoptosis and cell cycle distribution. Western blotting was used to assess the protein expression of related signaling proteins. Result:Compared with the two single drug groups treated with Tan ⅡA and DDP respectively, the combination group showed significantly higher anti-proliferative rate (P<0.01), arrested cell cycle at S phase, and resulted in observably higher apoptotic cell fractions in human hypopharyngeal squamous cell carcinomas Fadu cells; Western blotting showed that the protein expression of cleaved caspase 3 and cleaved PARP increased ,while survivin significantly decreased in the cells treated with the combination of tanshinone ⅡA and cisplatin.
Conclusion: Tanshinone ⅡA potentiates the efficacy of Cisplatin in Fadu cells, which may be attributed to the downregulation of survivin protein expression. Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery.

Entities:  

Keywords:  Cisplatin; Fadu cells; apoptosis; tanshinone IIA

Mesh:

Substances:

Year:  2017        PMID: 29771043     DOI: 10.13201/j.issn.1001-1781.2017.10.011

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 2096-7993


  4 in total

1.  Inhibition of cell survival and invasion by Tanshinone IIA via FTH1: A key therapeutic target and biomarker in head and neck squamous cell carcinoma.

Authors:  Wei Mao; Jian Ding; Yu Li; Ruofei Huang; Baoxin Wang
Journal:  Exp Ther Med       Date:  2022-06-16       Impact factor: 2.751

2.  Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway.

Authors:  Xiao-Zhong Liao; Ying Gao; Sheng Huang; Zhuang-Zhong Chen; Ling-Ling Sun; Jia-Hui Liu; Han-Rui Chen; Ling Yu; Jia-Xing Zhang; Li-Zhu Lin
Journal:  Phytother Res       Date:  2019-07-03       Impact factor: 5.878

3.  Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway.

Authors:  Rui Wang; Zhilin Luo; Hong Zhang; Tianhu Wang
Journal:  Onco Targets Ther       Date:  2019-11-07       Impact factor: 4.147

Review 4.  Salvia miltiorrhiza in cancer: Potential role in regulating MicroRNAs and epigenetic enzymes.

Authors:  Meng Lu; Xintian Lan; Xi Wu; Xiaoxue Fang; Yegang Zhang; Haoming Luo; Wenyi Gao; Donglu Wu
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.